The way this trial works is that there's a continual assessment of the outcomes of the patients who have enrolled around the world. We will have the ability to learn more quickly by participating than we ever would be able to by doing it alone in Canada.
We don't yet have any signal to say that we should stop any of our treatments because of efficacy or because of harm. We're still premature on that basis. You've seen this week that there have been a couple of announcements: one through peer-reviewed literature, and one through a press conference in the U.S. about one medication. I would say it's premature to make any judgment about that one medication.